Combined Brachytherapy and Ultra-Hypofractionated Radiotherapy for Intermediate-Risk Prostate Cancer: Comparison of Toxicity Outcomes Using a High-Dose Rate (HDR) vs. Low-Dose Rate (LDR) Brachytherapy Boost

被引：0
|
作者：
Kollmeier, M. A. [1 ]
Gorovets, D. [1 ]
Flynn, J. [2 ]
McBride, S. [2 ]
Brennan, V. S. [1 ]
Beaudry, J. [3 ]
Cohen, G. [2 ]
Damato, A. L. [3 ]
Zhang, Z. [4 ]
Zelefsky, M. J. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 114卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2506
引用
收藏
页码：E226 / E226
页数：1
相关论文
共 50 条
  • [21] Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients
    Marina, Ovidiu
    Gustafson, Gary S.
    Kestin, Larry L.
    Brabbins, Donald S.
    Chen, Peter Y.
    Ye, Hong
    Martinez, Alvaro A.
    Ghilezan, Michel I.
    Wallace, Michelle
    Krauss, Daniel J.
    [J]. BRACHYTHERAPY, 2014, 13 (01) : 59 - 67
  • [22] High dose rate (HDR) brachytherapy boost for prostate cancer gives high control rate
    Flynn, J. P.
    Kelly, D. A.
    Brookover, T.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S323 - S324
  • [23] Early toxicity in a randomized trial of high dose-rate (HDR) brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.
    Morton, Gerard
    Chung, Hans T.
    McGuffin, Merrylee
    Zhang, Liying
    Ravi, Ananth
    D'Alimonte, Laura
    Loblaw, Andrew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [24] High-dose versus low-dose rate brachytherapy in definitive radiotherapy of cervical cancer
    Kucera, H
    Pötter, R
    Knocke, TH
    Baldass, M
    Kucera, E
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2001, 113 (1-2) : 58 - 62
  • [25] Advantages of High-Dose Rate (HDR) Brachytherapy in Treatment of Prostate Cancer
    Molokov, A. A.
    Vanina, E. A.
    Tseluyko, S. S.
    [J]. PHYSICS OF CANCER: INTERDISCIPLINARY PROBLEMS AND CLINICAL APPLICATIONS (PC IPCA), 2017, 1882
  • [26] Combined Low Dose Rate Brachytherapy and External Beam Radiation Therapy for Intermediate-Risk Prostate Cancer
    Chao, Michael
    Joon, Daryl Lim
    Khoo, Vincent
    Spencer, Sandra
    Ho, Huong
    Guerrieri, Mario
    Foroudi, Farshad
    Bolton, Damien
    [J]. JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES, 2019, 50 (01) : 82 - 86
  • [27] Intermediate-Risk Prostate Cancer Treated With Definitive Low-dose-rate Brachytherapy
    Ester, E. C.
    Wang, X.
    Vernon, M. R.
    Olson, N. J.
    Shanley, R. M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S405 - S405
  • [28] High-dose-rate brachytherapy boost for prostate cancer: Outcomes and genitourinary toxicity
    Bece, Andrej
    Patanjali, Nitya
    Jackson, Michael
    Whitaker, May
    Hruby, George
    [J]. BRACHYTHERAPY, 2015, 14 (05) : 670 - 676
  • [29] Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer
    Spratt, Daniel E.
    Zumsteg, Zachary S.
    Ghadjar, Pirus
    Kollmeier, Marisa A.
    Pei, Xin
    Cohen, Gilad
    Polkinghorn, William
    Yamada, Yoshiya
    Zelefsky, Michael J.
    [J]. BJU INTERNATIONAL, 2014, 114 (03) : 360 - 367
  • [30] The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy
    Krishnan, Vimal
    Delouya, Guila
    Bahary, Jean-Paul
    Larrivee, Sandra
    Taussky, Daniel
    [J]. BJU INTERNATIONAL, 2014, 114 (06) : 865 - 871
12345